Form 4: AnaptysBio CFO's RSU Vesting and Tax-Related Stock Sale

AnaptysBio's Chief Financial Officer, Dennis Mulroy, reported the vesting of 6,700 restricted stock units and a subsequent sale of 2,515 shares to cover tax withholding obligations.

Summary

• Chief Financial Officer Dennis Mulroy reported transactions on January 7 and 8, 2026.
• 6,700 Restricted Stock Units (RSUs) vested on January 7, 2026, converting into 6,700 shares of common stock.
• Following the vesting, 2,515 shares of common stock were sold on January 8, 2026, at a price of $44.71 per share.
• This sale was a "sell to cover" transaction to satisfy tax withholding obligations related to the RSU vesting and was not a discretionary sale.
• After these transactions, Mulroy beneficially owns 21,852 shares of common stock and 20,100 unvested Restricted Stock Units.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to RSU vesting and a tax-related stock sale, which are standard compensation events and do not indicate a discretionary positive or negative sentiment towards the company's operational performance or future prospects.

Positives

• Vesting of 6,700 Restricted Stock Units (RSUs) for the Chief Financial Officer indicates continued compensation and retention of key management.

Negatives

• A sale of 2,515 shares of common stock by the CFO, even for tax purposes, slightly reduces direct insider ownership.

Future Outlook

NA

Industry Context

This filing details a routine insider transaction related to executive compensation and tax obligations, which is not directly indicative of broader industry trends or competitive positioning.

Related Party Transactions

• Vesting of 6,700 Restricted Stock Units (RSUs) to Chief Financial Officer Dennis Mulroy as part of his compensation package.
• Sale of 2,515 shares by Dennis Mulroy to cover tax withholding obligations related to the RSU vesting.

Stakeholder Impact

• Shareholders: The transaction represents a routine compensation event for a key executive, with minimal direct impact on the company's overall share structure or valuation.
• Employees: Demonstrates the company's standard executive compensation practices, including equity-based incentives.

Next Steps

• Remaining 20,100 Restricted Stock Units (RSUs) will vest annually at 25% of the total commencing January 7, 2026, subject to continued service.

Key Dates

Recommendation

This Form 4 details a routine insider transaction involving the vesting of restricted stock units and a subsequent 'sell to cover' sale for tax purposes. Such transactions are standard compensation events and do not provide new fundamental information to warrant a change in investment recommendation. The company's core business and future prospects remain the primary drivers for investment decisions.

Keywords

ANAPTYSBIO, ANAB, Form 4, insider trading, stock sale, RSU, restricted stock unit, CFO, beneficial ownership, tax withholding